Hi @Bouncing
The next trial that will start later this year, is an adaptive 2/3 trial for which the FDA has already advised they will consider accelerated approval at the 24 week mid trial results. This I understand is reliant on gaining Orphan Drug Designation status. The shelf life is also considerable so making a bulk batch will not go to waste.
Cheers
Ann: PharmAust makes Head of Manufacturing appointment, page-9
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.015(8.11%) |
Mkt cap ! $89.00M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.5¢ | 18.8¢ | $311.3K | 1.576M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 388155 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |